Crotalus adamanteus antivenin

Specification

• Cat#: THP-0159
• Product Name: Crotalus adamanteus antivenin
• Description: The product is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus adamanteus (Eastern Diamondback rattlesnake). The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. It is intravenously administered to limit systemic toxicity.
• Sequences: Not Available
• Species: Ovine
• Molecular Weight: Not Available
• Cas No: Not Available
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method

Pharmaceutical Information

• Pharmaceutical Application: Crotalus adamanteus antivenin
• Applications: Indicated for North American crotalid envenomation by Crotalinae rattlesnakes (eg, cottonmouths/water moccasins, copperheads, rattlesnakes).
• Examples of Clinical Use: Snake venom of Crotalinae rattlesnakes
• Pharmacodynamics: Reverses the effects of envenomation with Crotalus adamanteus.The Crotalidae family produces venoms which are generally necrolytic and hemolyzing to tissues. Hemorrhagins in crotalid venom is toxic to the blood vessels and therefore cause hemorrhage and edema at the wound site, in addition to systemic hemorrhage and shock. Significant anemia is observed due to hemolysis and extravasation of blood due to damaged vessels. Disseminated intravascular coagulation (DIC) has been observed in some cases. The most frequent initial clinical pathological changes include echinocytosis, thrombocytopenia, leukocytosis and prolonged activated clotting time. In general, edema and erythema along with fang marks may be seen at the site of bite although it is tough to identify due to thick hair coat in animals.
• Mechanism of action: CROFAB consists of venom-specific Fab fragments of immunoglobulin G (IgG) that work by binding to and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body.
• Affected organisms: Humans and other mammals
• Targets: Target 1. Group 10 secretory phospholipase A2; Enzyme 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1; Enzyme 2. Group 10 secretory phospholipase A2